Clinical trials: Post Menopause
Osteoporosis, Postmenopausal
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
The purpose of this study is to compare the effect of arzoxifene to raloxifene on the bone mineral density (bone strength).
- Trial name
- NCT00383422
- Testing
- Arzoxifene, Raloxifene
- Where
- 21 sites in United States, Argentina and 6 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Glucose Monitoring, Continuous, Whole Body Protein Metabolism
Effects of Amylopectin Chromium Blend on Whole-Body Protein Kinetics and Glucose in Peri/Post-Menopausal Women
The goal of this study is to better understand how an amylopectin chromium blend may influence whole body protein balance in women during midlife, when hormonal changes can adversely affect protein metabolism and muscle…
- Conditions
- Glucose Monitoring, Continuous, Whole Body Protein Metabolism, Peri-menopausal Women, Post-menopause
- Trial name
- NCT07402382
- Testing
- Amylopectin-chromium blend, Concentrated Amylopectin-chromium blend
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Nutrition 21, Inc.
Osteoporosis
Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate
This is a two part study (screening and treatment). The first part (screening) is designed to evaluate the percentage of patients missed in diagnosing osteoporosis by general practitioners (GP's).
- Trial name
- NCT00327990
- Testing
- Ibandronate, Alendronate
- Where
- 38 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Amenorrhea, Postmenopause
A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women
The objective of this study is to determine the safety and effectiveness of 3 asoprisnil doses when administered to postmenopausal women with Premarin® 0.625 mg.
- Trial name
- NCT00152282
- Testing
- Asoprisnil/Premarin
- Volunteers
- 105 people
- Sponsor
- Abbott
Breast Cancer
PROACT - Pre-Operative Arimidex Compared To Tamoxifen
The purpose of this study is to compare tamoxifen, versus a newer treatment, ARIMIDEX, which we already know to be well tolerated.
- Trial name
- NCT00232661
- Testing
- ARIMIDEX (anastrazole), NOLVADEX (tamoxifen)
- Where
- 79 sites in United States, Belgium and 8 more
- Volunteers
- 452 people
- Sponsor
- AstraZeneca
Coronary Artery Disease, Heart Disease
A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease
The study is designed to see if stress echocardiography can be used as a screening exam in peri-, or post-menopausal women with a risk of developing of coronary artery disease and experiencing future cardiac events.
- Trial name
- NCT00162370
- Testing
- Perflutren Lipid Microsphere Injectable Suspension
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- Lantheus Medical Imaging
Osteoporosis
A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate
The purpose of this trial is to study the clinical safety, tolerability, and efficacy of zoledronic acid compared to an oral bisphosphonate in postmenopausal women with osteoporosis.
- Trial name
- NCT00100555
- Testing
- zoledronic acid
- Where
- 18 sites in United States
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Breast Cancer (Female)
Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
To provide access to palbociclib to post-menopausal women with HR-positive, HER2-negative advanced breast cancer who are deemed appropriate for letrozole therapy (Canada: first-line patients only).
- Trial name
- NCT02142868
- Testing
- Palbociclib, Letrozole
- Where
- 55 sites in United States, Canada
- Sponsor
- Pfizer
Advanced Malignancy, Advanced Solid Tumors
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Neoplasm, Metastasis
- Trial name
- SDX-0101 (NCT02743637)
- Testing
- SDX-7320
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- SynDevRx, Inc.
Healthy
Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women
This is a Phase I, open label, sequential, single ascending dose (SAD) study to evaluate the pharmacokinetic (PK), safety, and tolerability of Letrozole LEBE in healthy post-menopausal women.
- Trial name
- LEILA-1 (NCT06315205)
- Testing
- Letrozole LEBE 75 mg, Letrozole LEBE 150 mg, Letrozole LEBE 225 mg
- Where
- Czechia
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Rovi Pharmaceuticals Laboratories
Osteoporosis in Post-menopausal Women, Osteoporosis
Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture
The primary objective of this study is to evaluate the safety and tolerability of human umbilical cord-derived mesenchymal stem cells for injection (HMM910 ) in postmenopausal women with osteoporosis who are at high risk of…
- Trial name
- NCT06949137
- Testing
- Human Umbilical Cord-derived Mesenchymal stem cell
- Where
- China
- Volunteers
- 9 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Hot Flushes, Menopause, Postmenopause
Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes
This is a research study to evaluate the effectiveness, safety and side effects of several dose levels of esterified estrogens (EE) and methyltestosterone (MT) given individually and in combination compared to a placebo (a tablet…
- Trial name
- NCT00160342
- Testing
- Esterified Estrogens (EE) and Methyltestosterone (MT)
- Where
- 125 sites in United States, Canada and 1 more
- Volunteers
- 1,251 people
- Sponsor
- Solvay Pharmaceuticals
Vaginal Disease
Post Marketing Follow Up Study To Evaluate Performance Safety Quality of Menopausal Transition Women Treated With Ainara
The objective of the present PMCF study with a 6 month follow up period is to identify potential new and unknown risks associated with longer term use of Ainara® and (considering the duration of symptoms in GSM) to collect…
- Trial name
- NCT04362371
- Testing
- Ainara
- Where
- Romania
- Volunteers
- 73 people
- Sponsor
- Italfarmaco
Osteoporosis
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of 3 doses of ALX1-11 (recombinant human parathyroid hormone [rhPTH(1-84)])(50, 75 and 100 µg) in the treatment of postmenopausal…
- Trial name
- NCT00172107
- Testing
- ALX1-11 50 mcg, ALX1-11 75mcg, ALX1-11
- Where
- 19 sites in United States, Canada
- Volunteers
- 217 people
- Sponsor
- Shire
Breast Cancer
Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer
This study will evaluate whether patients who are intolerant and discontinue anastrozole due to grade 2-3 arthralgia-myalgia have a decrease in rheumatological symptoms while taking letrozole
- Trial name
- REAL (NCT00688909)
- Testing
- letrozole
- Where
- 48 sites in United States
- Volunteers
- 261 people
- Sponsor
- Novartis Pharmaceuticals
Post Menopausal Breast Cancer
Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
This international, multi-center, open-label, single-arm study evaluated the safety and tolerability profile of everolimus in post-menopausal women with HR positive, HER2 negative locally advanced or metastatic breast cancer…
- Trial name
- EVEREXES (NCT03176238)
- Testing
- everolimus, exemestane
- Where
- 55 sites in Australia, India and 11 more
- Volunteers
- 235 people
- Sponsor
- Novartis Pharmaceuticals
Post-Menopausal Osteopenia
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
This 2 arm study will evaluate the efficacy and safety of oral Bonviva 150mg once monthly compared with placebo in post-menopausal women with osteopenia.
- Trial name
- NCT00129623
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 12 sites in United States
- Volunteers
- 160 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
STRIDE - STimulating Immune Response In aDvanced brEast Cancer
EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the indication of breast cancer following the clinical hold on the investigational new drug application for tecemotide (L-BLP25).
- Trial name
- STRIDE (NCT00925548)
- Testing
- Tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
- Where
- 29 sites in United States, Australia and 10 more
- Volunteers
- 16 people
- Sponsor
- EMD Serono
Osteopenia, Osteoporosis
Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density
This study is designed to provide information on the safety, tolerability, pharmacokinetics (PK) and bone biomarker response following multiple BPS804 administration in multiple dosing regimens.
- Trial name
- NCT01406548
- Testing
- BPS804 20mg/Kg
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Immune System Disorder (Healthy Volunteer)
A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 500 mg oral BID dose of KD025 in healthy male and post-menopausal female participants.
- Trial name
- NCT05918614
- Testing
- Belumosudil mesylate
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Kadmon, a Sanofi Company